5-(2,5-dihydroxyphenyl)-2(1H)-pyridone | 144909-21-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-(2,5-dihydroxyphenyl)-2(1H)-pyridone
• 英文别名: 5-(2,5-dihydroxyphenyl)-1H-pyridin-2-one
• CAS: 144909-21-7
• 化学式: C₁₁H₉NO₃
• 分子量: 203.197
• InChiKey: BTJICUWFWQIODX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  69.6
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  5-(2,5-dimethoxyphenyl)-2-methoxypyridine 以 甲醇 、 水 、 氢溴酸 为溶剂， 生成 5-(2,5-dihydroxyphenyl)-2(1H)-pyridone
  参考文献：
  名称：

  Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF

  摘要：

  这项发明涉及具有蛋白酪氨酸激酶抑制活性的双重单环和/或双环芳基和/或杂环芳基化合物。更具体地，它涉及一种抑制患有以这种增殖为特征的疾病的患者中异常细胞增殖的方法，包括向其施用所述双重单环和/或双环芳基和/或杂环芳基化合物的EGF和/或PDGF受体抑制有效量，以及制备这些化合物及其在用于这种方法的制药组合物中的使用。

  公开号：

  US05480883A1

文献信息

• Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF
  申请人：Rhone-Poulenc Rorer Pharmaceuticals Inc.

  公开号：US05480883A1

  公开（公告）日：1996-01-02

  This invention relates to bis mono- and/or bicyclic aryl and/or heteroaryl compounds exhibiting protein tyrosine kinase inhibition activity. More specifically, it relates to the method of inhibiting abnormal cell proliferation in a patient suffering from a disorder characterized by such proliferation comprising the administration thereto of an EGF and/or PDGF receptor inhibiting effective amount of said bis mono- and/or bicyclic aryl and/or heteroaryl compound and to the preparation of said compounds and their use in pharmaceutical compositions used in this method.

  这项发明涉及具有蛋白酪氨酸激酶抑制活性的双重单环和/或双环芳基和/或杂环芳基化合物。更具体地，它涉及一种抑制患有以这种增殖为特征的疾病的患者中异常细胞增殖的方法，包括向其施用所述双重单环和/或双环芳基和/或杂环芳基化合物的EGF和/或PDGF受体抑制有效量，以及制备这些化合物及其在用于这种方法的制药组合物中的使用。
• Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF
  申请人：Rhone-Poulenc Rorer Pharmaceuticals Inc.

  公开号：US05656643A1

  公开（公告）日：1997-08-12

  This invention relates to bis mono- and/or bicyclic aryl and/or heteroaryl compounds exhibiting protein tyrosine kinase inhibition activity. More specifically, it relates to the method of inhibiting abnormal cell proliferation in a patient suffering from a disorder characterized by such proliferation comprising the administration thereto of an EGF and/or PDGF receptor inhibiting effective amount of said bis mono- and/or bicyclic aryl and/or heteroaryl compound and to the preparation of said compounds and their use in pharmaceutical compositions used in this method.

  本发明涉及双取代的单环和/或双环芳基和/或杂芳基化合物，其表现出蛋白酪氨酸激酶抑制活性。更具体地，本发明涉及一种通过向患有异常细胞增殖的疾病的患者施加EGF和/或PDGF受体抑制有效量的所述双取代的单环和/或双环芳基和/或杂芳基化合物的方法，以抑制异常细胞增殖，并涉及制备所述化合物及其在用于该方法的制药组合物中的使用。
• Aerosol pirfenidone and pyridone analog compounds and uses thereof
  申请人：Avalyn Pharma Inc.

  公开号：US10028966B2

  公开（公告）日：2018-07-24

  Disclosed herein are formulations of pirfenidone or pyridone analog compounds for aerosolization and use of such formulations for aerosol administration of pirfenidone or pyridone analog compounds for the prevention or treatment of various fibrotic and inflammatory diseases, including disease associated with the lung, heart, kidney, liver, eye and central nervous system. In some embodiments, pirfenidone or pyridone analog compound formulations and delivery options described herein allow for efficacious local delivery of pirfenidone or pyridone analog compound. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures, indications and manufacturing processes for production and use of the compositions described.

  本文公开了用于气雾化的吡非尼酮或吡啶酮类似物化合物制剂，以及使用此类制剂气雾给药吡非尼酮或吡啶酮类似物化合物以预防或治疗各种纤维化和炎症性疾病，包括与肺、心、肾、肝、眼和中枢神经系统有关的疾病。在某些实施方案中，本文所述的吡非尼酮或吡啶酮类似化合物制剂和给药方案可实现吡非尼酮或吡啶酮类似化合物的有效局部给药。组合物包括本文所述的所有制剂、试剂盒和装置组合。方法包括用于生产和使用所述组合物的吸入程序、适应症和生产工艺。
• Aerosol pirfenidone and pyridone analog compound and uses thereof
  申请人：Avalyn Pharma Inc.

  公开号：US11071741B2

  公开（公告）日：2021-07-27

  Disclosed herein are formulations of pirfenidone or pyridone analog compounds for aerosolization and use of such formulations for aerosol administration of pirfenidone or pyridone analog compounds for the prevention or treatment of various fibrotic and inflammatory diseases, including disease associated with the lung, heart, kidney, liver, eye and central nervous system. In some embodiments, pirfenidone or pyridone analog compound formulations and delivery options described herein allow for efficacious local delivery of pirfenidone or pyridone analog compound. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures, indications and manufacturing processes for production and use of the compositions described.

  本文公开了用于气雾化的吡非尼酮或吡啶酮类似物化合物制剂，以及使用此类制剂气雾给药吡非尼酮或吡啶酮类似物化合物以预防或治疗各种纤维化和炎症性疾病，包括与肺、心、肾、肝、眼和中枢神经系统有关的疾病。在某些实施方案中，本文所述的吡非尼酮或吡啶酮类似化合物制剂和给药方案可实现吡非尼酮或吡啶酮类似化合物的有效局部给药。组合物包括本文所述的所有制剂、试剂盒和装置组合。方法包括用于生产和使用所述组合物的吸入程序、适应症和生产工艺。
• EP0584222A4
  申请人：——

  公开号：EP0584222A4

  公开（公告）日：1994-07-06